TheMathCompany Announces $50 Million Investment from Brighton Park Capital
TheMathCompany, a global data analytics and data engineering firm that partners with companies to enhance their analytics capabilities, today announced that it has secured $50 million in investments. The round of funding was led by Brighton Park Capital, an investment firm that specializes in collaborating with growth-stage software, healthcare, and tech-enabled services businesses. Existing investor, Arihant Patni, also participated in this round. The minority investment will accelerate TheMathCompany’s expansion in the US and EU markets, as well as enhance its next-generation, proprietary platform, Co.dx, which drives value for businesses through analytics at speed and scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220113005153/en/
(Photo: Business Wire)
Founded by industry leaders, Sayandeb Banerjee, Aditya Kumbakonam, and Anuj Krishna, TheMathCompany is a high-growth firm that employs nearly 1,000 data scientists, data engineers, and domain experts. The company represents and partners with Fortune 500 customers across the CPG, Retail, Pharma, Automotive, Technology, and Manufacturing industries in the US, UK, and EU. Enabling clients with a diverse set of capabilities powered by Co.dx, the organization implements data science and engineering initiatives across business functions, including marketing, supply chain, R&D, and finance. TheMathCompany’s hybrid model unifies Co.dx with a comprehensive consulting approach to deliver custom, cutting-edge analytics and AI-driven assets, helping customers implement successful and strategic business decisions.
“We are thrilled to announce Brighton Park Capital’s investment,” said Sayandeb Banerjee, CEO of TheMathCompany. “The firm’s deep technology sector expertise and proven track record of scaling global enterprises will be instrumental to our growth.”
“We look forward to partnering with TheMathCompany’s founders and the entire team to support their continued growth,” said Mark F. Dzialga, Managing Partner of Brighton Park Capital. “TheMathCompany is positioned for continued success as it strengthens its brand recognition and expands in the US and EU markets, supporting customers on their missions to capture value through data analytics.”
“TheMathCompany is poised to become one of the largest data and analytics consultancies in the world, supported by a world-class team of data engineers and scientists, and complemented by the power of the Co.dx platform to deliver more value, faster, for customers. I couldn’t be more excited to partner with Sayandeb, Aditya, and Anuj on the significant opportunities ahead,” said Jeff Machlin, Partner of Brighton Park. As part of the transaction, Jeff Machlin will join the Board of Directors.
“While most players in the industry have taken decades to grow to our size, we have built this strong foundation within five years. Brighton Park Capital’s partnership will further accelerate our plans to become the world’s leading global analytics consultancy,” said Aditya Kumbakonam, Chief Customer & Growth Officer at TheMathCompany. “As we grow and evolve, this investment will help us continue to bring elevated service and consistent quality to our customers.”
Anuj Krishna, Chief Product Officer at TheMathCompany, said, “With Brighton Park Capital as investors, we are excited to continue creating better opportunities for our people to grow their careers, while expanding the business globally. TheMathCompany will continue to invest heavily in Co.dx – a significant and meaningful differentiator in our journey to help enterprises scale and solve problems faster.”
TheMathCompany employs leading data scientists and engineers globally while also recruiting emerging talent from top-tier universities. New hires participate in a comprehensive onboarding and training program with the company’s in-house growth accelerator, Co.ach. The program is designed to help employees upskill across analytics disciplines and adapt to the industry’s ever-changing dynamics. In addition to fostering continued career development, the firm incentivizes employees with a stock ownership program, enabling them to participate in TheMathCompany’s continued growth and future success.
Avendus Capital served as financial advisor and Shardul Amarchand Mangaldas & Company served as legal counsel to TheMathCompany. Bharucha & Partners and Paul Weiss served as legal counsel to Brighton Park Capital.
About TheMathCompany
TheMathCompany is a global data analytics and data engineering firm that partners with Fortune 500 and equivalent organizations to enhance their analytics capabilities, using IP-led assets, talent, and processes to deliver accelerated and human-centric solutions. TheMathCompany has been recognized as one of the fastest-growing analytics firms in the world and has been featured among global high-growth firms by Nikkei-FT-Statista’s 2021 Growth Champions list, NASSCOM’s AI Gamechangers 2021 report, and the Everest Group’s PEAK Matrix® Assessment 2021. Providing a holistic range of services across data engineering, science, and unique project delivery, the company is disrupting the analytics industry. For more information about TheMathCompany, please visit www.themathcompany.com.
About Brighton Park Capital
Brighton Park is a Greenwich, CT-based investment firm that specializes in software, healthcare, and technology-enabled services. The firm invests in companies that provide highly innovative solutions in partnership with great management teams. Brighton Park brings purpose-built value-add capabilities that match the unique requirements of each of its companies. For more information about Brighton Park, please visit www.bpc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220113005153/en/
Contact information
For TheMathCompany:
Vignesh Subramanyam
vignesh.subramanyam@themathcompany.com
For Brighton Park Capital:
Emily Claffey / Alex Harron
Sard Verbinnen & Co
BrightonPark-SVC@SARDVERB.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA ™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 14:00:00 EEST | Press release
Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the durable benefit that vimseltinib can offer patients.” Summary of Data and Findings from the 2-year results of the MOTION Phase
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 17:09:00 EEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 17:00:00 EEST | Press release
Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the study increased considerably to 76.2% (95% CI: 63.8, 86.0) by blinded independent review committee (BICR) per RECIST v1.1, from 54% at Week 25. The study also showed continued clinically meaningful improvements in key secondary endpoints related to patient outcomes such as pain and function. The safety profile was consistent with previously reported data. The results are being presented today in the Sarcoma mini-oral session at the European Society for Medical
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 16:04:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B cell-mediated diseases. Pove is the only BAFF+APRIL inhibitor in pivotal trials for multiple kidney diseases. Next Steps for Pove Development In IgAN Following the announcement that the Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to pove for the treatment of IgAN, FDA recently granted a rolling review of the Biologics License Application (BLA) for pove for this indication. Vertex expects to submit the first module to FDA for potential accelerated approval before t
Qualcomm Announces Quarterly Cash Dividend17.10.2025 16:00:00 EEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom